Image Place holder

Joseph Markowitz, MD, PhD


Specialty: Medical Oncology
Program: Cutaneous Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Dr. Markowitz is interested in cutaneous oncology and melanoma in particular. He will engage in clinical translational research efforts in tumor immunology and immunotherapy.

Education & Training

Board Certification:

  • Medical Oncology
  • Internal Medicine

Fellowship:

  • The Ohio State University - Medical Oncology
  • The Ohio State University -
  • The Ohio State University - Advanced Medical Oncology

Residency:

  • The Ohio State University - Internal Medicine

Medical School:

  • University of Maryland Baltimore - MD, PhD
Participating Trials

CLINICAL TRIAL 19396
A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma
Condition: Cutaneous
Intervention: IMO-2125; Ipilimumab; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19634
Study of Resistance Mechanisms to Checkpoint Blockade
Condition: Cutaneous
Intervention:
Open

CLINICAL TRIAL 19500
Phase 1 Study Using a Plasmid DNA Coding for Emm55 Streptococcal Antigen in Patients with Unresectable Stage III or Stage IV Cutaneous Melanoma
Condition: Cutaneous
Intervention: IFx-Hu2.0
Open

CLINICAL TRIAL 18569
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma
Condition: Cutaneous
Intervention: Alkeran (Melphalan); DTIC (Dacarbazine); Dacarbazine; Ipilimumab; Melphalan; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18933
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition: Cutaneous
Intervention: Ipilimumab; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18975
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Condition: Cutaneous
Intervention: REGN2810
Open

CLINICAL TRIAL 18992
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)
Condition: Cutaneous
Intervention: Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-033; TSR-042
Open

CLINICAL TRIAL 19127
A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab Followed by Nivolumab Monotherapy
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19441
Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Condition: Cutaneous
Intervention: Cobimetinib; Not Applicable; RO5185426 (Vemurafenib); Vemurafenib (Zelboraf)
Open

CLINICAL TRIAL 19485
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma
Condition: Cutaneous
Intervention: IMCgp100
Open

CLINICAL TRIAL 19475
Phase 2 Study of Ceritinib in Patients with Unresectable Melanoma
Condition: Cutaneous
Intervention: Ceritinib (Zykadia)
Open

CLINICAL TRIAL 19601
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986213; Nivolumab; Not Applicable
Open

CLINICAL TRIAL 19407
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage IIIB/C Melanoma Patients
Condition: Cutaneous
Intervention: Daromun; Not Applicable
Open

CLINICAL TRIAL 18786
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18826
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Condition: Genitourinary
Intervention: ALKS 4230; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19686
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); BMS-986213; Nivolumab
Open

CLINICAL TRIAL 18989
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Condition: Cutaneous
Intervention: PV-10; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19109
A Phase 1/2, Open-Label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); NKTR-214; Nivolumab
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Latchana N, DiVincenzo MJ, Regan K, Abrams Z, Zhang X, Jacob NK, Gru AA, Fadda P, Markowitz J, Howard JH, Carson WE. Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol. 2018 Sep;118(3):501-509. Pubmedid: 30132912. Pmcid: PMC6160327.
  • Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Combined BRAF and HSP90 Inhibition in Patients with Unresectable -Mutant Melanoma. Clin Cancer Res. 2018 Nov;24(22):5516-5524. Pubmedid: 29674508. Pmcid: PMC6195480.
  • Johnson DB, Bordeaux JM, Kim JY, Vaupel CA, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy JW, Witte JS, McKee SB, Ko J, Wrangle J, Dabbas B, Tangri S, Lameh J, Hall JM, Markowitz J, Balko JM, Dakappagari NK. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018 Nov;24(21):5250-5260. Pubmedid: 30021908. Pmcid: PMC6214750.
  • Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE. Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4T cells in cancer and measurement of STAT1 nitration. Sci Rep. 2018 Mar;8(1):4203. Pubmedid: 29511220. Pmcid: PMC5840347.
  • Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018 Mar;8:44. Pubmedid: 29552542. Pmcid: PMC5840208.
  • Perez MC, Yu HM, Markowitz J. Severe thromboembolic phenomenon in the setting of pseudoprogression of melanoma brain metastases in response to combination immunotherapy. BMJ Case Rep. 2018 Aug;2018. Pubmedid: 30108120.
  • Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson Iii WE. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immun. 2017 Nov;66(11):1437-1447. Pubmedid: 28688082. Pmcid: PMC5647220.
  • Markowitz J, Wang J, Vangundy Z, You J, Yildiz V, Yu L, Foote IP, Branson OE, Stiff AR, Brooks TR, Biesiadecki B, Olencki T, Tridandapani S, Freitas MA, Papenfuss T, Phelps MA, Carson WE. Nitric oxide mediated inhibition of antigen presentation from DCs to CD4 T cells in cancer and measurement of STAT1 nitration. Sci Rep. 2017 Nov;7(1):15424. Pubmedid: 29133913. Pmcid: PMC5684213.
  • Yarlagadda K, Hassani J, Foote IP, Markowitz J. The role of nitric oxide in melanoma. BBA. Reviews on cancer. 2017 Dec;1868(2):500-509. Pubmedid: 28963068.
  • Latchana N, Abrams ZB, Howard JH, Regan K, Jacob N, Fadda P, Terando A, Markowitz J, Agnese D, Payne P, Carson WE. Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. Bioinform Biol Insights. 2017;11:1177932217694837. Pubmedid: 28469417. Pmcid: PMC5345922.
  • Creelan BC, Gabrilovich DI, Gray JE, Williams CC, Tanvetyanon T, Haura EB, Weber JS, Gibney GT, Markowitz J, Proksch JW, Reisman SA, McKee MD, Chin MP, Meyer CJ, Antonia SJ. Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. Onco Targets Ther. 2017;10:4239-4250. Pubmedid: 28919776. Pmcid: PMC5587199.
  • Markowitz J, Mal TK, Yuan C, Courtney NB, Patel M, Stiff AR, Blachly J, Walker C, Eisfeld AK, de la Chapelle A, Carson WE. Structural characterization of NRAS isoform 5. Protein Sci. 2016 May;25(5):1069-1074. Pubmedid: 26947772. Pmcid: PMC4838646.
  • Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Nole TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, Karpa V, Zhang X, Carson WE. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016 Dec;7(49):81172-81186. Pubmedid: 27783987. Pmcid: PMC5348384.
  • Liu JQ, Talebian F, Wu L, Liu Z, Li MS, Wu L, Zhu J, Markowitz J, Carson WE, Basu S, Bai XF. A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma. J Immunol. 2016 08;197(4):1489-1497. Pubmedid: 27385779. Pmcid: PMC4975953.
  • Markowitz J, Abrams Z, Jacob NK, Zhang X, Hassani JN, Latchana N, Wei L, Regan KE, Brooks TR, Uppati SR, Levine KM, Bekaii-Saab T, Kendra KL, Lesinski GB, Howard JH, Olencki T, Payne PR, Carson WE. MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. Onco Targets Ther. 2016;9:5931-5941. Pubmedid: 27729802. Pmcid: PMC5047719.
  • Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016;4:85. Pubmedid: 28031816. Pmcid: PMC5170897.
  • Markowitz J, Brooks TR, Duggan MC, Paul BK, Pan X, Wei L, Abrams Z, Luedke E, Lesinski GB, Mundy-Bosse B, Bekaii-Saab T, Carson WE. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunol Immun. 2015 Feb;64(2):149-159. Pubmedid: 25305035. Pmcid: PMC4504424.
  • Lankenau MA, Patel R, Liyanarachchi S, Maharry SE, Hoag KW, Duggan M, Walker CJ, Markowitz J, Carson WE, Eisfeld AK, de la Chapelle A. MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies. Proc Natl Acad Sci U S A. 2015 Dec;112(49):E6744-E6751. Pubmedid: 26582795. Pmcid: PMC4679059.
  • Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson GA, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc Natl Acad Sci U S A. 2014 Mar;111(11):4179-4184. Pubmedid: 24586049. Pmcid: PMC3964043.
  • Dhar A, Mallick S, Ghosh P, Maiti A, Ahmed I, Bhattacharya S, Mandal T, Manna A, Roy K, Singh S, Nayak DK, Wilder PT, Markowitz J, Weber D, Ghosh MK, Chattopadhyay S, Guha R, Konar A, Bandyopadhyay S, Roy S. Simultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptide. Biopolymers. 2014 Jul;102(4):344-358. Pubmedid: 24839139. Pmcid: PMC4107132.
  • Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, Olencki T, Kendra KL, Carson WE. A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma. J Immunother. 2014 Jan;37(1):55-62. Pubmedid: 24316557. Pmcid: PMC4174542.
  • Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz J, Hoag KW, Jarvinen TM, Leffel B, Perrotti D, Carson WE, Marcucci G, Bloomfield CD, de la Chapelle A. Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. Sci Signal. 2014 Apr;7(321):ra36. Pubmedid: 24736457. Pmcid: PMC4165404.
  • Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013 Jul;140(1):13-21. Pubmedid: 23828498. Pmcid: PMC3773691.
  • Markowitz J, Carson WE. Review of S100A9 biology and its role in cancer. Biochim Biophys Acta. 2013 Jan;1835(1):100-109. Pubmedid: 23123827. Pmcid: PMC3670606.
  • Wesolowski R, Markowitz J, Carson WE. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer. 2013;1:10. Pubmedid: 24829747. Pmcid: PMC4019895.
  • Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep;15(18):5895-5901. Pubmedid: 19737952. Pmcid: PMC2774354.
  • Markowitz JD, Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont). 2008 Oct;5(10):29-36. Pubmedid: 19724721. Pmcid: PMC2695757.
  • Markowitz J, MacKerell AD, Weber DJ. A search for inhibitors of S100B, a member of the S100 family of calcium-binding proteins. Mini Rev Med Chem. 2007 Jun;7(6):609-616. Pubmedid: 17584159.
  • Wright NT, Varney KM, Ellis KC, Markowitz J, Gitti RK, Zimmer DB, Weber DJ. The three-dimensional solution structure of Ca(2+)-bound S100A1 as determined by NMR spectroscopy. J Mol Biol. 2005 Oct;353(2):410-426. Pubmedid: 16169012.
  • Markowitz J, Rustandi RR, Varney KM, Wilder PT, Udan R, Wu SL, Horrocks WD, Weber DJ. Calcium-binding properties of wild-type and EF-hand mutants of S100B in the presence and absence of a peptide derived from the C-terminal negative regulatory domain of p53. Biochemistry-Us. 2005 May;44(19):7305-7314. Pubmedid: 15882069.
  • Markowitz J, Mackerell AD, Carrier F, Charpentier TH, Weber DJ. Design of Inhibitors for S100B. Curr Top Med Chem. 2005;5(12):1093-1108. Pubmedid: 16248785.
  • Markowitz J, Chen I, Gitti R, Baldisseri DM, Pan Y, Udan R, Carrier F, MacKerell AD, Weber DJ. Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. J Med Chem. 2004 Oct;47(21):5085-5093. Pubmedid: 15456252.
  • Lin J, Yang Q, Yan Z, Markowitz J, Wilder PT, Carrier F, Weber DJ. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004 Aug;279(32):34071-34077. Pubmedid: 15178678.
  • Lee ME, Markowitz J, Lee JO, Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett. 2002 Oct;530(1-3):53-58. Pubmedid: 12387865.